Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies

Thrombosis Research

Volumn 84, Issue 5, 1996, Pages 361-365

  Simantov, Ronit ^a   Lo, Siu K ^a   Salmon, Jane E ^b   Sammaritano, Lisa R ^b   Silverstein, Roy L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

antiphospholipid; factor V; systemic lupus erythematosus; thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY;

ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; BIOLOGICAL MARKERS; FACTOR V; HETEROZYGOTE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; THROMBOSIS;

EID: 0030561510     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(96)00200-9     Document Type: Article

References (17)

1. SAMMARITANO L.R., GHARAVI A.E., LOCKSHIN M.D. Antiphospholipid antibody syndrome: immunologic and clinical aspects. Sem Arth and Rheum. 20:1990;81-96.
2. SIMANTOV R., LASALA J.M., LO S.K., GHARAVI A., SAMMARITANO L.R., SALMON J.E., SILVERSTEIN R.L. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 96:1995;2211-2219.
3. DAHLBÄCK B., CARLSSON M., SVENSSON P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 330:1993;517-521.
4. GREENGARD J.S., SUN X., XU X., FERNANDEZ J.A., GRIFFIN J.H., EVATT B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 343:1994;1362-1363.
5. SVENSSON P.J., DAHLBÄCK B. Resistance to activated protein C as a basis for venous thrombosis. New Eng J Med. 330:1994;517-522.
6. TAN E.M., COHEN A.S., FRIES J.F., MASI A.T., MCSHANE D.J., ROTHFIELD J.C., SCHALLER J.C., TALAL N., WINCHESTER P.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth and Rheum. 25:1982;1271-1277.
7. GHARAVI A.E., HARRIS E.N., ASHERSON R.A., HUGHES G.R.V. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 46:1987;1-6.
8. ZOLLER B., SVENSSON P.J., HE X., DAHLBÄCK B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 94:1994;2521-2524.
9. BERTINA R.M., KOELEMAN B.P., KOSTER T., ROSENDAAL F.R., DIRVEN R.J., DE RONDE H., VAN DER VELDEN P.A., REITSMA P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
10. ZOLLER B., HOLM J., SVENSSON P., DAHLBÄCK B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost. 75:1996;270-274.
11. MARTINELLI I., BOTTASSO B., DUCA F., FAIONI E., MANNUCCI P.M. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost. 75:1996;703-705.
12. GREENGARD J.S., EICHINGER S., GRIFFIN J.H., BAUER K. Brief Report: Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg→Gln mutation in the gene for factor V. New Eng J Med. 331:1994;1559-1562.
13. LOVE P.E., SANTORO S.A. Antiphospholipid Antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: Prevalence and clinical significance. Ann Int Med. 112:1990;682-698.
14. DIZON-TOWSON D., HUTCHINSON C., SILVER R., WARE BRANCH D., WARD K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haem. 74:1995;1029-1031.
15. HOOPER W.C., DILLEY A., RIBEIRO M.J.A., BENSON J., AUSTIN H., SILVA V., RAWLINS P., WENGER N.K., EVATT B.L. A racial difference in the prevalence of the Arg506→Gln mutation. Thromb Res. 81:1996;577-581.
16. OZAWA T., NIIYA K., SAKURAGAWA N. Absence of factor V Leiden in the Japanese. Thromb Res. 81:1996;595-596.
17. BOKAREWA M.I., BREMME K., FALK G., STEN-LINDER M, EGBERG N., BLOMBÄCK M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res. 78:1995;193-200.